Article Type
Changed
Wed, 06/01/2022 - 13:08

Key clinical point: The rates of achieving low disease activity (LDA) and clinical remission were almost 20%-40% lower in patients with rheumatoid arthritis (RA) and elevated levels of adipocytokines.

 

Major finding: Patients in the highest vs lowest quartile of adiponectin (adjusted hazard ratio [aHR] 0.69) and leptin (aHR 0.77; both P < .05) had a significantly lower rate of achieving LDA. The odds of achieving clinical remission were lower in patients in the highest vs lowest quartile of adiponectin (aHR 0.69) and leptin (aHR 0.64; both P < .05).

 

Study details: This was an observational cohort study including 1274 veterans with RA and a disease activity score in 28 joints of >3.2.

 

Disclosures: This study did not declare any specific funding. JF Baker, BR England, and TR Mikuls reported receiving funding, grants, research support, or consulting fees from various sources.

 

Source: Baker JF et al. Adipocytokines and achievement of low disease activity in rheumatoid arthritis. Semin Arthritis Rheum. 2022;55:152003 (Apr 12). Doi: 10.1016/j.semarthrit.2022.152003

Publications
Topics
Sections

Key clinical point: The rates of achieving low disease activity (LDA) and clinical remission were almost 20%-40% lower in patients with rheumatoid arthritis (RA) and elevated levels of adipocytokines.

 

Major finding: Patients in the highest vs lowest quartile of adiponectin (adjusted hazard ratio [aHR] 0.69) and leptin (aHR 0.77; both P < .05) had a significantly lower rate of achieving LDA. The odds of achieving clinical remission were lower in patients in the highest vs lowest quartile of adiponectin (aHR 0.69) and leptin (aHR 0.64; both P < .05).

 

Study details: This was an observational cohort study including 1274 veterans with RA and a disease activity score in 28 joints of >3.2.

 

Disclosures: This study did not declare any specific funding. JF Baker, BR England, and TR Mikuls reported receiving funding, grants, research support, or consulting fees from various sources.

 

Source: Baker JF et al. Adipocytokines and achievement of low disease activity in rheumatoid arthritis. Semin Arthritis Rheum. 2022;55:152003 (Apr 12). Doi: 10.1016/j.semarthrit.2022.152003

Key clinical point: The rates of achieving low disease activity (LDA) and clinical remission were almost 20%-40% lower in patients with rheumatoid arthritis (RA) and elevated levels of adipocytokines.

 

Major finding: Patients in the highest vs lowest quartile of adiponectin (adjusted hazard ratio [aHR] 0.69) and leptin (aHR 0.77; both P < .05) had a significantly lower rate of achieving LDA. The odds of achieving clinical remission were lower in patients in the highest vs lowest quartile of adiponectin (aHR 0.69) and leptin (aHR 0.64; both P < .05).

 

Study details: This was an observational cohort study including 1274 veterans with RA and a disease activity score in 28 joints of >3.2.

 

Disclosures: This study did not declare any specific funding. JF Baker, BR England, and TR Mikuls reported receiving funding, grants, research support, or consulting fees from various sources.

 

Source: Baker JF et al. Adipocytokines and achievement of low disease activity in rheumatoid arthritis. Semin Arthritis Rheum. 2022;55:152003 (Apr 12). Doi: 10.1016/j.semarthrit.2022.152003

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: RA June 2022
Gate On Date
Tue, 05/24/2022 - 16:15
Un-Gate On Date
Tue, 05/24/2022 - 16:15
Use ProPublica
CFC Schedule Remove Status
Tue, 05/24/2022 - 16:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article